ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, closed a $65 million Series A financing round successfully. The Lausanne-based company plans to use the proceeds to advance its pipeline of multiple Phase 2 programs.

ReproNovo是一家致力于开发生殖医学和女性健康创新疗法的公司，成功完成了6500万美元的A轮融资。这家位于洛桑的公司计划利用这笔资金推进其多个二期临床项目的产品线。

ReproNovo

ReproNovo

, founded in 2021, is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility as well as uterine health. The company, led by a team with expertise in this space — Jean Marie Duvall (CEO), Joan-Carles Arce, MD, PhD (CSO & CMO), and BingMei Hao (CFO) — brings a proven track record in successful clinical development and commercial launches.

，成立于2021年，正在开发新的方法来解决生殖医学和女性健康领域的关键空白，包括男性和女性不孕症以及子宫健康问题。公司由在这一领域具有专长的团队领导——Jean Marie Duvall（首席执行官）、Joan-Carles Arce医学博士兼哲学博士（首席科学官兼首席医学官）和BingMei Hao（首席财务官），在临床开发和商业发布方面有着经得起考验的成功记录。

Headquartered in Lausanne, Switzerland, the company has its primary development team in Copenhagen, Denmark, and an additional development site in Barcelona, Spain. CEO Jean Marie Duvall and CFO BingMei Hao are based in the Lausanne Area..

总部位于瑞士洛桑的这家公司，其主要开发团队在丹麦哥本哈根，另外在西班牙巴塞罗那也有一个开发点。首席执行官 Jean Marie Duvall 和首席财务官 BingMei Hao 坐镇洛桑地区。

Since its inception, ReproNovo has rapidly built a pipeline comprising two Phase 2 clinical-stage assets across three disease areas. With its lead candidate, RPN-001 (leflutrozole), the company will focus on the development of an orally administered therapy for infertility in men with low serum testosterone.

自成立以来，ReproNovo 迅速建立了涵盖三个疾病领域的两条二期临床阶段资产的管线。其主导候选药物 RPN-001（来氟特罗唑）将专注于开发一种用于治疗低血清睾酮男性不育症的口服疗法。

Low testosterone is becoming more prevalent, even in younger men, highlighting the urgent need for new, more efficacious options. This trend coincides with a broader decline in male reproductive health, now recognized as a major public health problem..

低睾酮水平现象日益普遍，甚至出现在年轻男性中，突显出对新的更有效治疗选项的迫切需求。这一趋势恰逢男性生殖健康的整体下降，目前已被认为是一个主要的公共卫生问题。

RPN-002 (nolasiban), another orally administered therapy, is a first-in-disease and first-in-class molecular entity to manage adenomyosis, an overgrowth of endometrial tissue into the uterus that can result in severe menstrual bleeding and pain. Similar to endometriosis, this is a common gynecological condition, with recent imaging studies identifying features of adenomyosis in nearly one in four women undergoing gynecological evaluation.

RPN-002（nolasiban）是另一种口服治疗药物，作为首例针对疾病和首类分子实体，用于管理子宫腺肌症。子宫腺肌症是指子宫内膜组织过度生长进入子宫肌层，可能导致严重的月经出血和疼痛。与子宫内膜异位症类似，这是一种常见的妇科疾病，最近的影像学研究表明，在接受妇科评估的女性中，近四分之一的女性显示出子宫腺肌症的特征。

RPN-002 will also be explored for improving success rates in assisted reproductive technologies (ART)..

RPN-002 还将被研究用于提高辅助生殖技术 (ART) 的成功率。

Jean Marie Duvall, Co-Founder and Chief Executive Officer of ReproNovo stated: “We are focused on innovative therapeutic solutions for male and female infertility, as well as pioneering management options for conditions like adenomyosis. Our aim is to address critical gaps in the landscape of infertility and women’s health worldwide.

让-玛丽·杜瓦尔，ReproNovo的联合创始人兼首席执行官表示：“我们专注于为男性和女性不孕症提供创新的治疗方案，同时也在探索针对子宫腺肌症等疾病的开创性管理方法。我们的目标是解决全球范围内不孕症和女性健康领域中的关键问题。”

We are thrilled to announce the successful closing of our $65 million Series A funding round with a strong, sector specialized group of investors, marking a significant milestone in our journey toward becoming a leading reproductive medicine and women’s health company.”.

我们很高兴地宣布，我们已成功完成了6500万美元的A轮融资，投资方是一支实力雄厚、专注于该领域的专业投资者团队，这标志着我们在成为生殖医学和女性健康领域领先公司的征程上迈出了重要的一步。”

The round was led by

本轮融资由

Jeito Capital

资本方式

, co-led by

，共同领导

AXA IM Alts

AXA投资管理另类投资部

and founding investor

创始投资人

M Ventures

M风险投资

, with strong syndicate support from

，得到来自强大财团的支持

Ysios Capital

YSIOS资本

and

和

ALSA Ventures

ALSA风险投资公司

. Ksenija Pavletic, Partner & Chief Commercial Officer, Jeito Capital; Zina Affas Besse, Partner & Deputy Head of Healthcare Private Equity, AXA IM Alts; Hakan Goker, Managing Director & Head of Biotechnology investments, M Ventures; and Guillem Laporta, Partner, Ysios Capital are members of the ReproNovo Board of Directors as of closing..

Ksenija Pavletic，Jeito Capital的合伙人兼首席商务官；Zina Affas Besse，AXA IM Alts医疗保健私募股权部门的合伙人兼副主管；Hakan Goker，M Ventures的董事总经理兼生物技术投资主管；以及Guillem Laporta，Ysios Capital的合伙人，自交易结束起成为ReproNovo董事会成员。

Ksenija Pavletic, Partner & Chief Commercial Officer, Jeito Capital, stated: “As around one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialization of treatments with transformative benefits for patients.

Jeito Capital的合伙人兼首席商务官克塞尼娅·帕夫莱蒂奇表示：“由于全球大约每六个人中就有一人将面临不孕不育问题，我们很自豪能够支持ReproNovo，该公司致力于推进生殖健康领域的创新疗法，与我们专注于加速尖端技术以及具有变革性患者利益的治疗方案商业化的理念高度契合。”

We were highly impressed by the ReproNovo team, whose members have a strong track record in this field, having brought a number of compounds successfully through clinical development and onto the market.  Their deep understanding of the field will enable them to effectively address critical unmet needs that have a strong impact on society.”.

我们对ReproNovo团队印象深刻，其成员在这一领域有着强大的履历，成功将多种化合物通过临床开发并推向市场。他们对该领域的深刻理解将使他们能够有效解决对社会有重大影响的关键未满足需求。"

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送